Printer Friendly

LIDAK PHARMACEUTICALS AND CHIRON ENTER INTO COLLABORATIVE RESEARCH AGREEMENT ON AIDS

 LIDAK PHARMACEUTICALS AND CHIRON ENTER INTO
 COLLABORATIVE RESEARCH AGREEMENT ON AIDS
 LA JOLLA, Calif., March 23 /PRNewswire/ --- LIDAK Pharmaceuticals (NASDAQ: LDAKU, LDAKA) and Chiron Corp. (NASDAQ: CHIR) have initiated a collaborative research program to test the potential new immune therapies against AIDS. The studies utilize the proprietary human immune system-reconstituted SCID mouse technology of LIDAK and Chiron's proprietary vaccines directed against certain properties of HIV.
 In the LIDAK model mice with severe combined immune deficiency (SCID) are grafted with mature human peripheral blood cells to create hu-PBL-SCID mice. The grafted human cells make these mice susceptible to HIV infection. In previous contract studies, the hu-PBL-SCID mouse model has been shown to be useful for demonstrating the presence or absence of therapeutic efficacy of anti-AIDS compounds in diminishing or halting progression of HIV infection in such mice.
 LIDAK Pharmaceuticals is attempting to develop and commercialize pharmaceutical and other commercially significant products for the health care industry. In addition to its hu-PBL-SCID technology LIDAK is currently focusing its efforts on the commercialization of LIDAKOL as a treatment for herpes and other indications. Finally, the company is developing its Large Multivalent Immunogen technology as potential new therapies against cancer and viral diseases, and its Free Fatty Acid technology as a possible clinical diagnostic assay for the prediction and monitoring of cancer and diabetes.
 -0- 3/23/92
 /CONTACT: Michael H. Lorber, VP and CFO of LIDAK Pharmaceuticals, 619-558-0364; or Roger S. Pondel or Elizabeth A. Gard of Rifkind Pondel & Parsons, 310-207-9300, for LIDAK Pharmaceuticals/
 (LDAKU LDAKA CHIR) CO: LIDAK Pharmaceuticals; Chiron Corp. ST: California IN: MTC SU: JVN


EH -- LA002 -- 0408 03/23/92 09:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1992
Words:274
Previous Article:LCI INTERNATIONAL TO OFFER ITS ALL AMERICA PLAN CUSTOMERS ONE HOUR OF CALLING FOR ONE CENT PER MINUTE ON EASTER, MOTHER'S DAY
Next Article:WEITEK, VLSI TECHNOLOGY ENTER STRATEGIC ALLIANCE
Topics:


Related Articles
LIDAK PHARMACEUTICALS AWARDED FEDERAL GRANT TO DEVELOP HUMAN MONOCLONAL ANTIBODIES
RIBI IMMUNOCHEM AND LIDAK PHARMACEUTICALS TO COLLABORATE ON POTENTIAL SECOND-GENERATION THERACCINE TECHNOLOGY
LIDAK PHARMACEUTICALS AND RIBI IMMUNOCHEM RESEARCH COLLABORATE ON POTENTIAL CANCER VACCINE
Pharmacia Biotech and Ribozyme Pharmaceuticals, Inc. Announce Renewal of Research Collaboration
Chiron Grants Non-Exclusive HCV License to Bristol-Myers Squibb Company.
Xenogen Corporation Grants Chiron Corporation Commercial License to Patented Real-Time in Vivo Imaging Technology.
Chiron and XOMA Form Collaboration For Development and Commercialization Of Therapeutic Antibodies For Cancer; - Agreement Leverages Companies'...
Genetronics and Chiron Extend Collaborative Agreement on Technology for HIV Vaccine Delivery.
Genetronics and Chiron Extend Collaborative Agreement to Explore Delivery of HIV Vaccine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters